News Release icon Contact: Media Relations Office (518) 956-8150



'Catch and Release'

Chemist Maksim Royzen in his Life Sciences Building laboratory. 

ALBANY, N.Y. (Aug. 8, 2016) -- Some 12,000 people were diagnosed with soft-tissue sarcomas in 2015, and 5,000 died of the disease, according to the American Cancer Society. Even those who do survive are often left debilitated from the treatment — a combination surgery and chemotherapy.

University at Albany researcher Max Royzen believes he’s discovered a better path to recovery.

Teaming up with Jose Mejia Oneto of Shasqi, Inc., Royzen, an assistant professor in the Department of Chemistry, is using bio-orthogonal chemistry to eliminate sarcomas with minimal side effects and greater efficacy.

Their method, dubbed as “catch and release” limits toxic damage on a patient’s body by only using chemotherapy drugs in vicinity to the tumor site. To make it work, the researchers have developed a technology that positions biomaterial to activate systemically-administered chemo agents near the sarcoma location.

“Soft tissue sarcomas are particularly hard to treat due to the diverse composition and location of the tumors. Few treatment advances have been made in the past four decades,” said Royzen. “Our work with Shasqi has the potential to give patients of this rare cancer a more desirable treatment option and stronger chance at recovery.”

The researchers tested their innovation on mice, observing that site-activation of doxorubicin (a commonly-used chemotherapy drug) not only treated the sarcoma, but also kept it from coming back. In addition, their method had fewer side effects than those associated with traditional doxorubicin treatment including limited hair and weight loss and no decrease in red blood cells.

Royzen and Oneto said they plan to continue research in upcoming months. Specifically, they’re exploring ways to lower treatment toxicity even more. They also want to expand the approach to other types of cancerous tumors and drugs.

Their full study was published on July 13 in ACS Central Science. It has been picked up by various medical publications including Medgadget and Science Daily.

Learn more about Royzen by viewing his University faculty page. You can also visit his research group’s website.

comments powered by Disqus

RSS Link For more news, subscribe to UAlbany's RSS headline feeds

About the University at Albany
A comprehensive public research university, the University at Albany offers more than 120 undergraduate majors and minors and 125 master's, doctoral, and graduate certificate programs. UAlbany is a leader among all New York State colleges and universities in such diverse fields as atmospheric and environmental sciences, business, criminal justice, emergency preparedness, engineering and applied sciences, informatics, public administration, social welfare, and sociology taught by an extensive roster of faculty experts. It also offers expanded academic and research opportunities for students through an affiliation with Albany Law School. With a curriculum enhanced by 600 study-abroad opportunities, UAlbany launches great careers.